KidneyCAN’s Post

Renal Cell Carcinoma Illustration showing the enhancement of renal cell carcinoma across the 4 phases of CT. https://lnkd.in/eui6ynYx

Be sure to read this #clinicalinvestigation 🔍 #Percutaneous Microwave #Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes https://lnkd.in/dPfTsF2C

😆 New #Review sharing! Happy reading! 🔎 Exploring the therapeutic potential of lipid-based #nanoparticles in the management of oral squamous cell carcinoma 📖 This review aims to discuss current treatment approaches and their limitations, as well as recent advancements in LNPs for better management of OSCC. 🎉 Authors: Md. Rizwanullah, Ph.D. * et al. 😆 Welcome to read, forward, and share the article! 🔗https://lnkd.in/gheqXtvN #OralSquamousCellCarcinoma, #Pathogenesis #LipidBasedNanoparticles, #PassiveTargeting, #ActiveTargeting, #cytotoxicity

1 month follow up of Total Parotidectomy HPE: Epithelial myoepithelial Carcinoma (Well circumscribed, Lymph nodes negative) What is the role of adjuvant treatment in these cases?

From the July issue: MicroRNA signatures associated with basal cell carcinoma subtypes https://ow.ly/Phq250Se68f #dermtwitter #medderm #nmsc #bcc

Activation of p53 Signaling and Regression of Breast and Prostate Carcinoma Cells by Spirooxindole-Benzimidazole Small Molecules https://lnkd.in/dFZ5H3sx

KEYNOTE-689 is the first Phase 3 trial to demonstrate statistically significant and clinically meaningful improvement in EFS in the intent-to-treat population in the neoadjuvant and adjuvant setting for an anti-PD-1 therapy in earlier stages of head and neck squamous cell carcinoma https://lnkd.in/gmtjVjkZ

Last week marked a pivotal moment in the evolution of #celltherapy with the #FDA's #acceleratedapproval of a treatment for metastatic or unresectable synovial sarcoma. As the first new treatment for #synovialsarcoma in over a decade, and the first ever engineered T-cell therapy specifically designed for #solidtumors, #Tecelra opens new possibilities in the treatment of cancers that have long been challenging to address. With a 43% response rate in #clinicaltrials, this milestone not only brings hope to patients with few treatment options but also signals a significant advancement in the broader field of #CART cell therapy. The potential to harness engineered T-cells to target solid tumors is a landmark milestone in transforming #cancertreatment.

Durable antitumor activity (ORR 49%) and survival (51% at 2-years) in recurrent/metastatic Merkel Cell Carcinoma, a further step for the patients

See how high-throughput sequencing of the TCR repertoire contributes to molecularly defining TIL cell therapy products and gauging population diversity to provide fuller insight into the tumor microenvironment and therapy efficacy. Watch the full webinar from iRepertoire now: https://hubs.li/Q02Gz08j0 #TILs #Tcells #TumorMicroenvironment #EpthelialCancer #TcellReceptor #CellTherapy #TCRSequencing #TumorCells #CancerResearch